Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 10/20 | 0.39 |
| ▸ | PARP1 | P09874 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.32 |
| ▸ | CAT | P04040 | 1/20 | 0.32 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.31 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18797957 | 0.94 | MAPT (0.36) | SMYD3PARP1MAPTHMGB1CAT | |
| SCHEMBL18797960 | 0.92 | PARP1 (0.35) | SMYD3PARP1HMGB1CAT | |
| SCHEMBL17337372 | 0.91 | PARP1 (0.36) | SMYD3PARP1MAPTMTNR1AMTNR1B | |
| SCHEMBL17337112 | 0.91 | PARP1 (0.36) | SMYD3PARP1MAPTMTNR1AMTNR1B | |
| SCHEMBL17337118 | 0.90 | MTNR1A (0.42) | PARP1MTNR1AMTNR1B | |
| SCHEMBL17337121 | 0.90 | MTNR1A (0.42) | PARP1MTNR1AMTNR1B | |
| SCHEMBL17337409 | 0.89 | KMT2A (0.34) | PARP1MAPTMTNR1AMTNR1B | |
| SCHEMBL17337131 | 0.89 | PARP1 (0.33) | PARP1MAPTMTNR1AMTNR1B | |
| SCHEMBL17337126 | 0.89 | PARP1 (0.33) | PARP1MAPTMTNR1AMTNR1B | |
| SCHEMBL17337412 | 0.89 | KMT2A (0.34) | PARP1MAPTMTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11008346-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2021-05-18 | — | — | US | disclosed |
| US-20200361962-A1 | BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-11-19 | — | — | US | disclosed |
| US-9926336-B2 | Beta-lactamase inhibitors | VENATORX PHARMACEUTICALS (US) | 2018-03-27 | — | — | US | disclosed |
| US-20170342092-A1 | BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-11-30 | — | — | US | disclosed |
| US-9783555-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2017-10-10 | — | — | US | disclosed |
| US-9637504-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2017-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11008346-B2 | Beta-lactamase inhibitors | MGAM, GAA, LCT | SMYD3 926/4885PARP1 589/4885MAPT 4167/4885 |
| US-20170342092-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | SMYD3 926/4885PARP1 589/4885MAPT 4167/4885 |
| US-20200361962-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | SMYD3 926/4885PARP1 589/4885MAPT 4167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.